GE Healthcare’s Life Sciences business has entered into an agreement with Sealed Air to further develop new films for bioprocessing applications.
The companies will develop novel films for single-use bioprocess systems, as part of the strategic alliance formed to deliver solutions for the biopharmaceuticals industry.
Under the long term collaboration, the companies have already developed a new film for use across GE’s full single-use portfolio.
The new film was created to support application robustness, better plant growth and enhance security of supply.
Sealed Air’s Medical Applications business produces films for pharmaceutical solutions and barrier films for stoma and ostomy pouches. They are marketed under the Nexcel brand.
GE Healthcare’s Life Sciences business upstream products general manger Morgan Norris said: “GE and Sealed Air share a vision of the importance of robust, high quality films in the efficient manufacture of life saving medicines such as monoclonal antibodies, vaccines and next generation biotherapeutics.
“Through this partnership we are confident that we will deliver the next level of purposefully constructed and manufactured films for bioprocessing applications, enabling improved performance, supply chain control, and material/supplier transparency that the market demands of single-use suppliers.”
Sealed Air medical applications division general manager and vice president Gareth Crain said: “The combination of GEHC’s industry knowledge and breadth of product portfolio, with our experience, established proven compliance and quality systems in the pharmaceutical market space, will enable us to deliver film solutions uniquely suited to the needs of single-use technology users in biomanufacturing.”
